Zacks.com on MSN2d
Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out forSage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK CITY, NY / ACCESS Newswire / February 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...
NEW YORK CITY, NY / ACCESS Newswire / January 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...
From consumer to tech, here's a list of key deals reported this week: Molson Coors Beverage (TAP) has agreed to acquire an 8.5% stake in Fevertree Drinks, becom ...
The board of Sage Therapeutics unanimously rejected Biogen's acquisition offer of around $469 million, saying it "significantly undervalues" the company. That's not surprising – Sage filed a ...
Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...
Major stock indexes closed lower on Friday, after the week saw a flurry of events, including DeepSeek scare and earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback